October 24, 2016
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B. Read the Press Release
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B. Read the Press Release
BIOPHYTIS to implement company’s SARA-data e-Health platform for clinical development of Sarconeos in sarcopenia patients. Read the Press Release
Biophytis to attend the European Large & Midcap Event in Paris – 5-6 October, 2016
Video interview of Stanislas Veillet, CEO of Biophytis. Click here to see it
Business Update and Consolidated Half-Year Financials as of June 30, 2016. Read the Press Release
BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase. Read the Press Release
BIOPHYTIS ready to launch SARA-OBS trial. Read the Press Release
Biophytis will be present at BIOPHARM AMERICA 2016 in Boston, from September 13 to 15
BIOPHYTIS will present at the Rodman & Renshaw 18th Annual Global Investment Conference In New York City, September 11-13, 2016. Read the Press Release
Enrollment of the first subjects in the pharmacokinetics study on Sarcopenia. Read the Press Release